SYGNIS AG launches TrueAdvance amplification service to address quality needs in next-generation sequencing
Madrid, Spain, and Heidelberg, Germany, March 7, 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the launch of the DNA amplification and validation service TrueAdvance. Aim of the new service is to support and enable single cell and liquid biopsy applications and reinforce SYGNIS’ position in the NGS (Next Generation Sequencing) market.
TrueAdvance is targeting to support the initial workflow steps of NGS users. Through this newly launched service SYGNIS will provide customers both with a high quality amplification service, based on the patented TruePrime technology, as well as a sample validation service, based on the CovCheck technology, confirming the amplified DNA is of highest quality and suitable for NGS. Only validated samples will be returned to the customer for NGS analysis.
SYGNIS’ goal is to extend and enhance the support of customers with single cells or liquid biopsies needs and address not only DNA amplification, but also NGS and bioinformatics data analysis needs, ensuring the highest quality of the results at every stage of the work flow.
In oncology and other clinical applications, to secure that the DNA sample has been properly amplified and the data has been properly analyzed is highly relevant as clinical decisions will be taken based on these data. One of the main market needs is to support end users during the entire work flow, especially in single cell and liquid biopsy. In this case, the amplification step is an important barrier for many DNA researchers due to the complexity and sensitivity of the process. TrueAdvance breaks that barrier and enables all DNA researchers to enter into the single cell and liquid biopsy approach.
In January 2017 SYGNIS had launched its bioinformatics platform TrueHelix to support customers with the complex NGS data analysis, the final step in the NGS workflow. The first tool was a contamination checker, which identifies foreign DNA in a given sample.
Dr. Heikki Lanckriet, Co-CEO/CSO of SYGNIS said: “Single cell and liquid biopsy are truly challenging fields at the cutting edge of science. Through this new service we are offering world class expertise in these areas to our customers. In combination with our recently launched bioinformatics platform TrueHelix, we aim to support and add value for customers at every step in their work flow from sample collection to final data analysis. We are aiming to become partners of our customers and a reference Company for all NGS users.”
For further information, please contact:
MC Services AG
About SYGNIS AG: www.sygnis.com
SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).